AGEN - Agenus Inc.
| Previous Close | 3.9000 |
| Open | 3.9400 |
| Bid | 4.1800 x 1400 |
| Ask | 4.1900 x 1300 |
| Day's Range | 3.9400 - 4.2200 |
| 52 Week Range | 2.1300 - 4.5700 |
| Volume | 1,169,224 |
| Avg. Volume | 1,185,986 |
| Market Cap | 578.977M |
| Beta (5Y Monthly) | 2.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9620 |
| Earnings Date | Nov 03, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- PR Newswire
Agenus Announces Investor Day on February 20, 2020
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.
- Simply Wall St.
Did You Manage To Avoid Agenus's (NASDAQ:AGEN) 22% Share Price Drop?
It is doubtless a positive to see that the Agenus Inc. (NASDAQ:AGEN) share price has gained some 47% in the last three...
- PR Newswire
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.
- Zacks
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.
- Zacks
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
- PR Newswire
Agenus Commences Phase 1 trial with AGEN1223
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel bi-specific antibody discovered by Agenus and designed to deplete regulatory T cells in the tumor microenvironment. The first patient was infused in December 2019 and the trial is underway with a plan to initiate combinations with balstilimab, Agenus' investigational PD-1 inhibitor, in 2020.
- Zacks
Innate Pharma's Filing for Leukemia Drug Accepted in Europe
The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.
- Zacks
Pulmatrix Surges on License Agreement With Johnson & Johnson
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
- Zacks
Amicus Progresses on Pipeline Development Amid Competition
Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
- Zacks
Arena (ARNA) Expands Strategic Deal With Beacon Discovery
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
- Insider Monkey
Here is What Hedge Funds Think About Agenus Inc (AGEN)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- PR Newswire
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor. Agenus began this study as a monotherapy in patients with advanced solid tumors within a Phase 1 dose escalation study (NCT03860272) in April 2019.
- Zacks
All You Need to Know About Agenus (AGEN) Rating Upgrade to Buy
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents
Edited Transcript of AGEN earnings conference call or presentation 4-Nov-19 1:30pm GMT
Q3 2019 Agenus Inc Earnings Call
- Zacks
Agenus (AGEN) Up 24.5% Since Last Earnings Report: Can It Continue?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
- Zacks
Moving Average Crossover Alert: Agenus
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
- PR Newswire
Agenus to Host R&D Day November 15, 2019
LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, ...
- Zacks
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- PR Newswire
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd. Under the agreement Agenus is providing access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with UroGen's sustained release technology for intravesical delivery in patients with urinary tract cancers. Agenus is conducting clinical trials for zalifrelimab in combination with Agenus' anti-PD-1 antibody balstilimab (AGEN2034) for a planned BLA filing in cervical cancer.
- Zacks
Will Agenus Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Agenus.
- Benzinga
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...
- Zacks
Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
